Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC... May 10, 2023 4 Tips from Oncology Dietitians for Healthier Eating During Cancer January 2, 2024 Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with... June 11, 2026 What to Know About Navigating Cancer Care With a Disability: An... May 4, 2023 Load more HOT NEWS Get the Most out of Seasonal Fruits! More Treatment Options Emerging for Some Men with Metastatic Prostate Cancer What to Expect During Recovery From a Bone Marrow Transplant: An... Training Cancer Researchers: A Conversation with Dr. Oliver Bogler
